the aid library

LIST OPTIONS

Filter

2417

Sort by:

Direction:

Download (1201)

View PDF (1968)

Donaciones de dispositivos médicos: consideraciones relativas a su solicitud y suministro

Organización Panamericana de la Salud (2011) C_WHO

WHO Medical Devices Donations - SPANISH Version - Las tecnologías sanitarias son fundamentales en un sistema de salud operativo. Los dispositivos médicos, en concreto, son cruciales para la prevención, el diagnóstico, el tratamiento y la rehabilitación de enfermedades. Estos documentos están d... more

Download (169)

View PDF (288)

Disability Data Collection in Community-based Rehabilitation

Sunil Deepak, Franesca Ortali, Geraldine Mason Halls, Tulgamaa Damdinsuren, Enhbuyant Lhagvajav, Steven Msowoya, Malek Qutteina, Jayanth Kumar Disability, CBR & Inclusive Development Journal (DCIDJ) (2016) CC

Today there are Community-based Rehabilitation (CBR) programmes in a large number of countries. In many countries, the CBR approach is a part of the national rehabilitation services. However, there is a lack of reliable data about persons with disabilities who benefit from CBR and the kind of benefi... more

Download (341)

View PDF (441)

Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy

World Health Organization (WHO) (2017) C_WHO

The objectives of these guidelines are to provide recommendations outlining a public health approach to managing people presenting with advanced HIV disease, and to provide guidance on the timing of initiation of antiretroviral therapy (ART) for all people living with HIV.
WHO recommends that a... more

Download (1530)

View PDF (2359)

The World Medcines situation 2011 Rational use of Medicines

World Health Organization WHO (2011) C_WHO

Millennium Development Goal 8E aims for affordable access to essential medicines. Essential medicines, as defined by WHO, are those that “satisfy the health-care needs of the majority of the population” and that should therefore “be available at all times in adequate amounts”. However, there... more

Download (567)

View PDF (889)

Compendium of WHO guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis
recommended

World Health Organization WHO (2018) C_WHO

2nd edition. T The Compendium has been developed as a clear and concise instrument to facilitate the understanding and planning of delivery of high-quality care for everybody affected by TB. It incorporates all recent policy guidance from WHO; follows the care pathway of persons with signs or sympt... more

Download (144)

View PDF (173)

The Core Elements of Outpatient Antibiotic Stewardship

Centers for Disease Control and Prevention CDC (2019) C_CDC

The Core Elements of Outpatient Antibiotic Stewardship provides a framework for antibiotic stewardship for outpatient clinicians and facilities that routinely provide antibiotic treatment. This report augments existing guidance for other clinical settings. In 2014 and 2015, respectively, CDC release... more

Download (52)

View PDF (105)

Strengthening the Health Systems Response to COVID-19 - Technical guidance #3

World Health Organization (Europe) (2020) C_WHO

Supply of essential medicines and health technologies (6 April 2020) This paper is one of a set of technical guidance papers developed by the WHO Regional Office for Europe to provide practical information and resources for decision-makers on measures to strengthen the health system response to C... more

Download (149)

View PDF (161)

Whole-genome sequencing for surveillance of antimicrobial resistance

World Health Organization WHO; Global Antimicrobial Resistance and Use Surveillance System (GLASS) (2020) C_WHO

Whole-genome sequencing (WGS) provides a vast amount of information and the highest possible resolution for pathogen subtyping. The application of WGS for global surveillance can provide information on the early emergence and spread of AMR and further inform timely policy development on AMR control.... more

Download (112)

View PDF (158)

Continuity of essential health services: Facility assessment tool
recommended

World Health Organization WHO (2021) C_WHO

Interim guidance. 12 May 2021. The Continuity of essential health services: Facility Assessment Tool can be used by countries to rapidly assess the capacity of health facilities to maintain the provision of essential health services during the COVID-19 pandemic. It can help to alert the authorities ... more

Download (341)

View PDF (463)

Diarrhea and Dehydration Module 6

Yu C, Lougee D, Murno JR American Academy of Pediatrics (2016) C1

Poor sanitary conditions in disaster-stricken areas result in higher risk for diarrheal illness in vulnerable populations, especially children. This disease negatively impacts the nutritional status of affected children and causes significant morbidity and mortality. Early di... more

Download (120)

View PDF (149)

Definition and categorization of the timing of mother-to-child transmission of SARS-CoV-2

World Health Organization WHO (2021) C_WHO

The WHO COVID-19 LENS (Living Evidence Synthesis) working group consolidated available evidence, based on rapid reviews of the literature and results of a living systematic review on pregnancy and COVID-19 (up to October 7, 2020), on potential mechanisms of vertical transmission of infectious pathog... more

Download (116)

View PDF (120)

Continuité des services de santé essentiels : outil d’évaluation des établissements
recommended

Organisation Mondiale de la Santé OMS (2021) C_WHO

Module appartenant à la série d’évaluations des capacités des services de santé dans le cadre de la pandémie de COVID-19: orientations provisoires, 12 mai 2021. L'outil d'évaluation de la continuité des services de santé essentiels : Facility Assessment Tool peut être utilisé par les pa... more

Download (168)

View PDF (234)

Malaria vaccine: WHO position paper - March 2022
recommended

World Health Organization WHO (2022) C_WHO

Weekly Epidemiological Record No 9, 2022, 97, 61–80 This position paper supersedes the 2016 publication, “Malaria vaccine: WHO position paper-2016.”1 It includes the updated WHO recommendations on the wider use of the RTS,S/AS01 vaccine for the reduction of malaria morbidity and mortality in ... more

Download (138)

View PDF (153)

Pandemic influenza preparedness framework: progress report

World Health Organization WHO (2022) C_WHO

The Pandemic Influenza Preparedness (PIP) Framework is a World Health Assembly resolution adopted unanimously by all Member States in 2011. It brings together Member States, industry, other stakeholders and WHO to implement a global approach to pandemic influenza preparedness and response. The Frame... more

Download (75)

View PDF (70)

Health financing for the COVID-19 response: Process guide for national budgetary dialogue. ACT-A Health Systems Connector

World Health Organization (WHO), World Bank, Global Financing Facility (GFF) et al. World Health Organization (WHO) (2021) CC

Annual and medium-term budget preparation processes are the platforms through which specific plans are transformed into actual resource allocation decisions. The aim of this Process Guide is to support key stakeholders involved in these processes (such as the Cabinet, Ministries of Finance and Healt... more

Download (245)

View PDF (329)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (27)

View PDF (18)

2020 Heart Failure Society of South Africa perspective on the 2016 European Society of Cardiology Chronic Heart Failure Guidelines

Hitzeroth, J.; Mpe, M.; Klug, E. et al. The South African Medical Journal (2020) CC

Heart failure with a reduced ejection fraction (HFrEF) is a condition frequently encountered by healthcare professionals and, in order to achieve the best outcomes for patients, needs to be managed optimally. This guideline document is based on the European Society of Cardiology Guidelines for the t... more

Download (16)

View PDF (17)

National Guidelines for the Management of Cardiovascular Diseases

Ministry of Health Ghana Republic of Ghana (2019) CC

Cardiovascular diseases (CVDs) are a growing public health problem in Ghana and other African countries. Strokes and other CVDs have become a leading cause of death due to increasing risk factors such as hypertension. According to the Global Burden of Disease study (GBD), ischaemic heart disease was... more

Download (11)

View PDF (15)

Epidemiology and Challenges of Managing COPD in sub-Saharan Africa

Magitta, N.F.; Sciences, A. Acta Scientific Medical Sciences (2018) CC2

There is paucity of data on the burden and specific drivers operative in the pathogenesis of chronic obstructive pulmonary disease (COPD) in the African setting and populations. Lack of awareness and inadequate knowledge on the aetio-pathogenesis of the disease together with inadequate capacity for ... more

Download (3)

View PDF (3)

Mpox Testing Strategy - November 2024

Africa Center for Disease Control and Prevention (2024) CC

Mpox is an emerging zoonotic disease caused by the mpox virus, a member of the Orthopoxvirus genus closely related to the variola virus that causes smallpox. Mpox was first discovered in 1958 when outbreaks of a pox-like disease occurred in monkeys kept for research. The first human case was recorde...d in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox and since then the infection has been reported in a number of African countries. Mpox can spread in humans through close contact, usually skin-to-skin contact, including sexual contact, with an infected person or animal, as well as with materials contaminated with the virus such as clothing, beddings and towels, and respiratory droplets in prolonged face to face contact. People remain infectious from the onset of symptoms until all the lesions have scabbed and healed. The virus may spread from infected animals through handling infected meat or through bites or scratches. Diagnosis is confirmed by polymerase chain reaction (PCR) testing of material from a lesion for the virus’s DNA. Two separate clades of the mpox virus are currently circulating in Africa: Clade I, which includes subclades Ia and Ib, and Clade II, comprising subclades IIa and IIb. Clade Ia and Clade Ib have been associated with ongoing human-to-human transmission and are presently responsible for outbreaks in the Democratic Republic of the Congo (DRC), while Clade Ib is also contributing to outbreaks in Burundi and other countries. In 2022‒2023 mpox caused a global outbreak in over 110 countries, most of which had no previous history of the disease, primarily driven by human-to-human transmission of clade II through sexual contact. In just over a year, over 90,000 cases and 150 deaths were reported to the WHO. For the second time since 2022, mpox has been declared a global health emergency as the virus spreads rapidly across the African continent. On 13 Aug 2024, Africa CDC declared the ongoing mpox outbreak a Public Health Emergency of Continental Security (PHECS), marking the first such declaration by the agency since its inception in 2017.7 This declaration empowered the Africa CDC to lead and coordinate responses to the mpox outbreak across affected African countries. On August 14, 2024, the WHO declared the resurgence of mpox a Public Health Emergency of International Concern (PHEIC) emphasizing the need for coordinated international response. As of August 2024, Mpox has expanded beyond its traditional endemic regions, with new cases reported in countries including Sweden, Thailand, the Philippines, and Pakistan. Sweden has confirmed its first case of Clade 1 variant, which has been rapidly spreading in Africa, particularly in DRC. The emergence of this new variant raises concerns about its potential for higher lethality and transmission rates outside Africa. more

Compendium of WHO guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis recommended

Continuity of essential health services: Facility assessment tool recommended

Continuité des services de santé essentiels : outil d’évaluation des établissements recommended

Malaria vaccine: WHO position paper - March 2022 recommended

Compendium of WHO guidelines and associated standards: ensuring optimum delivery of the cascade of care for patients with tuberculosis
recommended

Continuity of essential health services: Facility assessment tool
recommended

Continuité des services de santé essentiels : outil d’évaluation des établissements
recommended

Malaria vaccine: WHO position paper - March 2022
recommended